QSAR Studies of PTP1B Inhibitors: Recent Advances and Perspectives
Abstract:Diabetes mellitus, a chronic condition caused by defects in insulin secretion, or action, or both, is a group of metabolic disorders, complications of which can contribute significantly to ill health, disability, poor quality of life and premature death. From the three main types of diabetes, Type 2 is by far the most common, accounting for about 90% of cases worldwide. Studies on the role of protein tyrosine phosphatase 1B (PTP1B) have clearly shown that it serves as a key negative regulator of insulin signaling and is involved in the insulin resistance associated with Type 2 diabetes. The present work aims to survey information related to PTP1B research published in the last decade. Emphasis is laid particularly on Quantitative Structure-Activity Relationships (QSAR) based studies that supported so far the design of new, potent and selective PTP1B inhibitors. Finally, the challenges and perspectives of QSAR studies in this field are discussed to show how these method can be used to design new chemical entities with enhanced PTP1B inhibition activity.
Keywords: 2D-QSAR; 3D-QSAR; Diabetes mellitus; comparative molecular field analysis (CoMFA); comparative molecular similarity indices analysis (CoMSIA); drug design; multiple linear regression (MLR); protein tyrosine phosphatase 1B inhibitors; quantitative structure-activity relationships (QSAR); radial basis function neural networks (RBFNN); type 2 diabetes; virtual screening
Document Type: Research Article
Publication date: September 1, 2012
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.